- Home
- BHC
as 11-06-2025 3:52pm EST
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
| Founded: | N/A | Country: | Canada |
| Employees: | N/A | City: | QUEBEC |
| Market Cap: | 2.2B | IPO Year: | N/A |
| Target Price: | $9.00 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.25 - $9.82 | Next Earning Date: | 10-29-2025 |
| Revenue: | $10,029,000,000 | Revenue Growth: | 5.86% |
| Revenue Growth (this year): | 6.81% | Revenue Growth (next year): | 4.11% |
Stock Insider Trading Activity of Bausch Health Companies Inc. (BHC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carson Seana | BHC | EVP, General Counsel | Sep 8 '25 | Sell | $7.31 | 13,370 | $97,734.70 | 499,585 | |
| Lee Frank D. | BHC | N/A | Aug 21 '25 | Sell | $7.66 | 15,912 | $121,885.92 | 73,795 | |
| Paulson John | BHC | N/A | Aug 14 '25 | Buy | $9.00 | 34,721,118 | $312,490,062.00 | 70,755,869 | |
| Paulson John | BHC | N/A | Aug 13 '25 | Buy | $7.06 | 86,409 | $610,047.54 | 70,755,869 | |
| Paulson John | BHC | N/A | Aug 12 '25 | Buy | $6.88 | 1,156,640 | $7,957,683.20 | 70,755,869 | |
| Paulson John | BHC | N/A | Aug 11 '25 | Buy | $6.35 | 2,000,000 | $12,700,000.00 | 70,755,869 |
Latest Bausch Health Companies Inc. News
BHC Breaking Stock News: Dive into BHC Ticker-Specific Updates for Smart Investing
Morningstar Research
17 days ago
Analyst Report: Bausch + Lomb Corporation
GlobeNewswire
a month ago
George Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil
ACCESS Newswire
a month ago
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
ACCESS Newswire
a month ago
Bausch Health to Announce Third Quarter 2025 Results on October 29
ACCESS Newswire
a month ago
Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry
MT Newswires
2 months ago
Bausch Health Completes US$63 Million Durect Acquisition, Adds Breakthrough Hepatitis Therapy to Pipeline
MT Newswires
2 months ago
Bausch Health Completes $63 Million Acquisition of Durect
PR Newswire
2 months ago
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
Compare BHC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BHC Bausch Health Companies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.